GlassScriptPhysician profile
Shannon D Buck
NPI 1497598965
$2,440.57
in general payments reported to CMS, 2019-2025
27 companies · $1,341 in 2025
The $1,341 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,100 · 2025: $1,341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,713 · Travel and Lodging: $727.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,713.44 |
| Travel and Lodging | $727.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $1,064.22 | 2024 | |
| Recordati_rare_diseases_inc. | $172.57 | 2025 | Isturisa |
| Insulet Corporation | $163.03 | 2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $98.27 | 2025 | Keveyis, Gvoke Hypopen, Recorlev |
| Amgen INC. | $86.27 | 2025 | Prolia, Evenity, Tepezza |
| Novo Nordisk INC | $85.17 | 2025 | Rybelsus, Ozempic, Wegovy |
| Corcept Therapeutics | $83.27 | 2025 | Korlym |
| Madrigal Pharmaceuticals | $76.86 | 2025 | Rezdiffra |
| Paratek Pharmaceuticals, INC. | $55.40 | 2024-2025 | Nuzyra |
| Radius Health, INC. | $53.83 | 2025 | Tymlos |
| Tandem Diabetes Care, INC. | $47.54 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sequel Med Tech, LLC | $42.92 | 2025 | Twiist |
| Sanofi-Aventis U.S. LLC | $42.65 | 2025 | |
| Cequr Corporation | $40.00 | 2025 | Cequr Simplicity |
| Scpharmaceuticals INC. | $37.48 | 2024-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $34.89 | 2025 | Qutenza |
| Astellas Pharma US INC | $33.07 | 2025 | Veozah |
| Medtronic, INC. | $27.32 | 2025 | Minimed 780g |
| Alexion Pharmaceuticals, INC. | $26.93 | 2025 | Strensiq |
| Chiesi USA, INC. | $26.81 | 2025 | Mycapssa |
| Ascendis Pharma Endocrinology INC | $26.44 | 2025 | Yorvipath |
| Kyowa Kirin, INC. | $25.16 | 2025 | |
| Neurocrine Biosciences, INC. | $24.53 | 2025 | |
| Globus Medical, INC. | $19.78 | 2025 | Senza |
| Esperion Therapeutics, INC. | $16.57 | 2025 | Nexletol |
| Organogenesis INC. | $15.25 | 2025 | Affinity |
| Tolmar, INC. | $14.34 | 2025 | Jatenzo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Buck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.